首页> 美国卫生研究院文献>International Scholarly Research Notices >Toxicity Evaluation of Pũrṇa Cantirotaya Centũram a Siddha Medicine in Wistar Rats
【2h】

Toxicity Evaluation of Pũrṇa Cantirotaya Centũram a Siddha Medicine in Wistar Rats

机译:悉达多药物PũrṇaCantirotayaCentũram对Wistar大鼠的毒性评估

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Pũrṇa Cantirotaya Centũram (PCC), a herbometallic formulation of Siddha medicine, consists of mercury, sulphur, and gold, processed with red cotton flower and plantain stem pith juices. To evaluate its safety, acute and 28-day repeated oral toxicity studies were performed following OECD test guidelines 423 and 407, respectively. In acute study, PCC was administered orally at 5, 50, 300, and 2000 mg/kg body weight. Animals were observed for toxic signs for 14 days. Gross pathology was performed at the end of the study. In repeated dose toxicity study, PCC was administered at 2.5, 25, and 50 mg/kg body weight daily for 28 days. Satellite groups (control and high dose) were also maintained to determine the delayed onset toxicity of PCC. In acute toxicity study, no treatment related death or toxic signs were observed. It revealed that the LD50 cut-off value of PCC is between 2000 and 5000 mg/kg body weight. The repeated dose study did not show evidence of any treatment related changes in all observations up to the high dose level, when compared with the control. Histopathological examination revealed no abnormalities except mild hyperplasia of stomach in high dose group. This study provides scientific validation for the safety of PCC.
机译:PũrũaCantirotayaCentũram(PCC)是悉达(Siddha)药物的金属化学配方,由汞,硫和金组成,并用红色棉花和车前草茎髓汁加工。为了评估其安全性,分别按照OECD测试指南423和407进行了急性和28天重复口服毒性研究。在急性研究中,以5、50、300和2000µmg / kg体重口服PCC。观察动物14天的毒性体征。在研究结束时进行大体病理检查。在重复剂量毒性研究中,每天以2.5、25和50μmg/ kg体重的剂量施用PCC,持续28天。还维持卫星组(对照组和高剂量组)以确定PCC的延迟发作毒性。在急性毒性研究中,未观察到与治疗相关的死亡或毒性迹象。结果表明,PCC的LD50截止值在2000至5000 mg / kg体重之间。与对照相比,重复剂量研究并未显示直至高剂量水平的所有观察结果中任何治疗相关变化的证据。高剂量组除轻度胃增生外,组织病理学检查未见异常。这项研究为PCC的安全性提供了科学验证。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号